$-0.40 EPS Expected for Proteostasis Therapeutics, Inc. (PTI)

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Logo

Analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to report $-0.40 EPS on November, 5.They anticipate $0.10 EPS change or 20.00 % from last quarter’s $-0.5 EPS. After having $-0.39 EPS previously, Proteostasis Therapeutics, Inc.’s analysts see 2.56 % EPS growth. The stock increased 2.76% or $0.0231 during the last trading session, reaching $0.8598. About 152,029 shares traded. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 64.36% since October 7, 2018 and is downtrending. It has underperformed by 64.36% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $42.37 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

More notable recent Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news were published by: Finance.Yahoo.com which released: “Will Proteostasis Therapeutics (PTI) Report Negative Q2 Earnings? What You Should Know – Yahoo Finance” on August 07, 2019, also Seekingalpha.com with their article: “The Upcoming Readout For Proteostasis Is In A Make Or Break Situation – Seeking Alpha” published on December 18, 2018, Globenewswire.com published: “Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients – GlobeNewswire” on September 16, 2019. More interesting news about Proteostasis Therapeutics, Inc. (NASDAQ:PTI) were released by: Globenewswire.com and their article: “Uniti Group Inc. Agrees to Sale of Latin America Tower Portfolio – GlobeNewswire” published on February 19, 2019 as well as Globenewswire.com‘s news article titled: “Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients – GlobeNewswire” with publication date: September 09, 2019.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.